Gain Therapeutics (NASDAQ:GANX) Releases Earnings Results, Beats Estimates By $0.03 EPS

Gain Therapeutics (NASDAQ:GANX) posted its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03, FiscalAI reports.

Gain Therapeutics Stock Performance

Shares of NASDAQ:GANX opened at $1.83 on Friday. The business has a fifty day moving average of $2.13 and a 200-day moving average of $2.36. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.52 and a current ratio of 2.52. Gain Therapeutics has a twelve month low of $1.41 and a twelve month high of $4.34. The firm has a market cap of $70.38 million, a PE ratio of -3.00 and a beta of -0.03.

Analyst Ratings Changes

GANX has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Friday, December 19th. Roth Mkm reaffirmed a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a report on Friday, December 19th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Gain Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $8.50.

Institutional Investors Weigh In On Gain Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GANX. Sprott Inc. bought a new position in shares of Gain Therapeutics in the fourth quarter worth about $39,000. Commonwealth Equity Services LLC acquired a new stake in shares of Gain Therapeutics in the fourth quarter valued at approximately $41,000. Millennium Management LLC bought a new position in Gain Therapeutics in the 4th quarter worth approximately $45,000. JPMorgan Chase & Co. acquired a new position in Gain Therapeutics during the 3rd quarter worth $47,000. Finally, Engineers Gate Manager LP bought a new position in Gain Therapeutics in the 4th quarter valued at $47,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.